Joel Baglole

Joel Baglole

InvestorPlace Contributor

Joel Baglole has been a financial reporter for more than 20 years. For five years, Mr. Baglole was a staff reporter at The Wall Street Journal, where he wrote articles from Iceland to Indonesia and covered topics ranging from the automotive and airline industries to investment banks and global stock markets.

Mr. Baglole has also worked for The Washington Post and Toronto Star newspapers, and has contributed to business focused websites such as The Motley Fool and Investopedia. At InvestorPlace, he covers a wide range of large and small cap stocks, as well as political and economic issues that impact financial markets.

Check out Joel’s TipRanks profile.

Recent Articles

Buy DraftKings Stock Before This Breakout Really Heats Up

By Joel Baglole, InvestorPlace Contributor

What to make of DraftKings stock? While the Boston-based fantasy sports and online betting company's share price has risen 6% in the past month, it remains down 14% over the last six months and is 30% below its all-time high of $74.38 reached in mid-March of this year. The stock has traded in a range of $50 to $55 since May and currently sits right at $52 per share.

AMD Stock Is Still a Buy as It Returns Toward Pre-Pullback Form

By Joel Baglole, InvestorPlace Contributor

Shares of Advanced Micro Devices are down 5% in the past week presenting an opportunity for investors to buy the dip. The pullback in AMD stock comes after the share price ripped 25% higher over the past month, hitting a 52-week high of $122.49 before falling back to its current price of $104.38. However, the dip is likely to be temporary and investors should buy shares of the semiconductor company before they move higher.

3 Movie Stocks to Buy That Could Be the Next AMC

By Joel Baglole, InvestorPlace Contributor

Shares of movie theater chain AMC continue to rise due to the meme stock rally. These three movie stocks could be targeted next.

Canopy Growth Stock Is Burdened By Cash Burn and Questionable Management

By Joel Baglole, InvestorPlace Contributor

Canopy Growth's stock is down 33% so far this year and the slide shows no signs of ending anytime soon. At $17.47, the Smiths Falls, Ontario-based company's shares are now at the same level they were at in the autumn of 2019 before the Covid-19 pandemic hit. The slump in Canopy Growth's stock was exacerbated recently after the company reported its latest quarterly earnings, which continued a trend of worrying financial results.

3 Buffett Biotech Stocks To Sell Like Berkshire

By Joel Baglole, InvestorPlace Contributor

Warren Buffett sold shares in multiple pharmaceutical companies during the second quarter. You may want to reconsider these biotech stocks.

Load More